Invesaro

Stocks Health care PRGO

NYSE · Health care

PERRIGO Co plc (PRGO)

PERRIGO Co plc brought in $4.1B of revenue over the twelve months to June 27, 2026, down 4.2% from a year earlier. It posted a net loss of $1.7B. Operating cash flow minus capital spending left $145.1M of free cash flow in fiscal 2025. At June 27, 2026 it held $399.7M in cash against $3.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.

Revenue (last 12 months)
$4.1B
-4.2% year on year
Net margin
-41.9%

What PERRIGO Co plc does

PERRIGO Co plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker PRGO.

Revenue and profit by year

Revenue
FY18: $4.7B $4.7B FY18FY19: $3.9B $3.9B FY19FY20: $4.1B $4.1B FY20FY21: $4.1B $4.1B FY21FY22: $4.5B $4.5B FY22FY23: $4.7B $4.7B FY23FY24: $4.4B $4.4B FY24FY25: $4.3B $4.3B FY25
Net income
FY18: $131M $131M FY18FY19: $146.1M $146.1M FY19FY20: -$162.6M -$162.6M FY20FY21: -$68.9M -$68.9M FY21FY22: -$140.6M -$140.6M FY22FY23: -$12.7M -$12.7M FY23FY24: -$171.8M -$171.8M FY24FY25: -$1.4B -$1.4B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$4.3B-$1.1B-$1.4B-$10.29$145.1M
2024$4.4B$112.9M-$171.8M-$1.25$244.6M
2023$4.7B$151.9M-$12.7M-$0.09$303.8M
2022$4.5B$78.9M-$140.6M-$1.04$210.9M
2021$4.1B$410.4M-$68.9M-$0.52$4.2M
2020$4.1B$265.2M-$162.6M-$1.19$465.8M

Latest SEC filings

What PERRIGO Co plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 8, 2026
    Passive stake changed SCHEDULE 13G/A
  2. August 14, 2026
    Passive stake changed SCHEDULE 13G/A
  3. August 5, 2026
    Quarterly report 10-Q · period to June 27, 2026
  4. August 5, 2026
    Quarterly results 8-K
  5. July 29, 2026
    Passive stake changed SCHEDULE 13G/A
  6. July 6, 2026
    Executive or director change 8-K/A
  7. July 6, 2026
    Executive or director change 8-K
  8. June 30, 2026
    Executive or director change 8-K
  9. June 24, 2026
    Employee plan annual report 11-K
  10. June 12, 2026
    Conflict minerals disclosure SD

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 15, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PRGO

What does PERRIGO Co plc do?

PERRIGO Co plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker PRGO.

Is PERRIGO Co plc profitable?

No. Over the twelve months to June 27, 2026 it reported a net loss of $1.7B on revenue of $4.1B.

How much revenue does PERRIGO Co plc make?

Over the twelve months to June 27, 2026 PERRIGO Co plc reported revenue of $4.1B. That is 4.2% less than a year earlier.

When did PERRIGO Co plc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 27, 2026. Its newest filing of any kind is the insider trade from September 15, 2026.

Similar companies

JNJ
Johnson & Johnson
LLY
ELI LILLY & Co
MRK
Merck & Co., Inc.
PFE
Pfizer Inc
ABBV
AbbVie Inc.
AZN
Astrazeneca PLC

Follow PRGO

Get an email when PERRIGO Co plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow PRGO: get an email when it files

Where the numbers come from

Financial figures are the values PERRIGO Co plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.